Key statistics
On Thursday, Allakos Inc (ALLK:NSQ) closed at 0.9069, 69.51% above the 52 week low of 0.535 set on Sep 23, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.9157 |
---|---|
High | 0.9393 |
Low | 0.89 |
Bid | 0.86 |
Offer | 0.90 |
Previous close | 0.9392 |
Average volume | 701.88k |
---|---|
Shares outstanding | 89.34m |
Free float | 87.28m |
P/E (TTM) | -- |
Market cap | 83.91m USD |
EPS (TTM) | -2.03 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
- Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers
- Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
- Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
- Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria
- Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
- Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
- Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
- Allakos Announces a Restructuring to Focus on Development of AK006
- Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
More ▼